Member Info for ogm4

Lots of work ongoing behind the scenes at the moment no doubt

Fair point, it was embedded in this end Dec22 RNS

They did not attend the JP Morgan event in 2023 as far as I can see. Instead they joined two conferences in Spain that year.

Looks like this is the first time they attended the JPM conference.

Fair point, I have to add though not only Tim but also Sebastien seems quite positive about the interest from other pharmaceuticals lately.

Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma Biotech said: "The findings we have announced today highlight the extremely diligent and focused research we have been conducting behind the scenes at Immupharma Biotech in order to better characterise and explain our lead asset P140 and its application in autoimmune diseases, which is now gaining significant attention within the biopharmaceutical industry."

Nearly 300 trades in less than 1 hour...

Going by the announcements on IMM's website they attended two conferences last year in Spain in March and May.

It looks like this time they have been exclusively invited by JP Morgan to join their conference (by invitation only) possibly for the first time.

Both CEO Tim and Sebastien planned to attend both the two JPM and Biotech Showcase conferences in SF. That does tell you something, doesn't it? They were out in full force as from what I can expect they had a compelling story to tell.

The advances made by ImmuPharma with the P140 program, particularly in the latter part of 2024, have led to SIGNIFICANT interest from leading Biopharmaceutical companies and WE ARE PROGRESSING DISCUSSIONS as WE MOVE to establish GLOBAL LICENSING AGREEMENTS.

2025 could be very interesting!...

There have been eleven $1bn+ licensing deals for immunology assets across the BioPharma industry from 2023 to late September 2024. The current trend suggests that Immunology and Autoimmune drug assets are becoming VERY HIGHLY SOUGHT by the leading BioPharma companies.

....

I noticed the news article below was released on 8 Jan 25 on their website, but wasn't RNS-ed on lse, at least not visible:

Immupharma at JP MORGAN CONFERENCE and BIOTECH SHOWCASE 11-16 January 2025, San Francisco

8th January 2025 - 10:24 am

https://www.immupharma.co.uk/immupharma-at-jp-morgan-conference-and-biotech-showcase-11-16-january-2025-san-francisco/

That was a nice £19k buy at 3.60p near the end of close yesterday afternoon.

With "GROUNDBREAKING" results I expect the CEO to come back shortly with either an RNS or follow up interview to further outlay the latest developments, including some feedback from the JPM conference last week.

Back to 3.60p

You just start to wonder if there is someone accumulating ahead of news

Big trade at 3.02p then?

3.50p paid, but it wasn't me!

I just managed to put an order in at 3.0p.

Doubt whether it will still go through though.

Can't buy at the minute...

probably my broker platform

Increased action all of a sudden...

Even if IMM could serve a minor fraction of the global peptides therapeutics market, say 1/1000th of 46 Billion USD, it would still easily be a 50+ Million USD company for argument sake. The potential is massive here, but indeed as with every investment comes wth a risk.

The global peptide therapeutics market for 2025 is estimated over 46 USD Billion. Definitely an interesting sector to be in.

There must be a clear interest in Immupharma for them to have been invited exclusively to such a premier bio healthcare conference.

So Immupharma were in fact invited to join the J.P. Morgan Healthcare conference being a very prominent event in its sector. They didn't request themselves then to join this conference. Bodes well imo.

JP Morgan Healthcare Conference

13-16 Jan San Francisco

By invitation only

Read the 3rd paragraph, sounds promising...

https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

Happy New Year to all genuine shareholders!...

Here is to a healthy and prosperous 2025 and Empire moving forward in the right direction with plenty of developments ahead.